Want to join the conversation?
$LLY leveraged 3% constant currency revenue growth into 16% operating income growth. Earlier in Oct., $LLY took back North American rights to Erbitux from Bristol-Myers Squibb. New City research and development site is planned for expansion to enhance $LLY's immune-oncology capabilities.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?